HUTCHMED (China) Limited (HK:0013) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
HUTCHMED (China) Limited has announced that its combination therapy of ORPATHYS® and TAGRISSO® has received Breakthrough Therapy Designation in China for certain lung cancer patients. This designation by China’s National Medical Products Administration highlights the potential of this combination to address unmet medical needs in patients with advanced or metastatic non-small cell lung cancer with MET amplification. The therapy is currently being tested in Phase III trials, aiming to offer a chemotherapy-free treatment option.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
